SGMT Sagimet Biosciences Inc: Accounting Value per Share

Symbol and logo of brand Sagimet Biosciences (SGMT)

Sagimet Biosciences (SGMT) ensures margin stability through the diversification of partner laboratories and streamlined logistics for biochemical components. This chart on GURU.Markets illustrates the business dynamics of a company creating unique inhibitors to combat liver pathologies. The current figure stands at 4.11, while the company relies on existing capital reserves as it awaits the completion of clinical trials for its promising small-molecule developments.

SGMT Sagimet Biosciences, Inc. Share Book Value (02/21/2024 - 10/30/2026)

Summary analytical data breakdowns for sagimet.com (SGMT)

- current quotes and average value forecast:
Price Chart Sagimet|SGMT - Consensus Target
- company stock capitalization data:
Market Valuation Sagimet Biosciences Inc.|SGMT - Aggregate Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Sagimet Biosciences|SGMT - Net Asset Value|Market Capitalization to Book Value Ratio sagimet.com|SGMT - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital Sagimet Biosciences|SGMT - Long-Term Debt to Capital|Short-Term Debt to Equity Sagimet Biosciences Inc.|SGMT - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Sagimet Biosciences Inc.|SGMT - Company Long-Term Liabilities|Company Short-Term Debts Sagimet Biosciences|Quick Liquidity Indicator sagimet.com
- earnings and multiples data:
SGMT - Final Profit
General company analysis:SGMT - Sagimet
Manufactured products of Sagimet Biosciences Inc.

The monopoly potential of Sagimet Biosciences (SGMT) patents for liver drugs makes its market capitalization dependent on the value of its intellectual assets. The BVPS trend reflects the difference between total assets and liabilities per share, demonstrating the company's actual equity volume and capital management efficiency, which serves as the foundation for assessing intrinsic value and investment reliability.

Competitor analysis

ASND - Net Assets per Single Share|Madrigal Corp (MDGL) - Accounting Value per Share|CORT (Corcept Therapeutics) - Accounting Value per Share|RYTM: Book Price of a Share|Net Assets per Single Share Akero|Metsera, Inc. - Share Book Value|Book Value per Share MLTX|CRNX (Crinetics Corp) - Accounting Value of a Share|Book Value per Share NAMS (NewAmsterdam Pharma)|Book Value per Share soleno.life SLNO|FOLD - Net Assets per Single Share|Accounting Value of a Share ETNB (89bio Inc)|Agios Pharmaceuticals Inc (AGIO) - Net Assets per Single Share|Accounting Value per Share Structure Corp|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com|Accounting Value per Share LXRX (Lexicon Pharmaceuticals, Inc.)|MBX (MBX Biosciences, Inc.) - Accounting Value of a Share|Net Assets per Single Share Altimmune Corp ALT|AARD - Accounting Value per Share|BioAge Labs, Inc. - Book Value per Share|Net Asset Value per Share biomeafusion.com|QNCX (quincetx.com) - Accounting Value per Share|GUTS: Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share PLUR|Net Assets per Single Share SYBX (synlogictx.com)|Net Assets per Single Share Lipocine LPCN|Matinas BioPharma Holdings, Inc. (MTNB) - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO: Net Assets per Single Share|CTCX: Book Value per Share|LUMO - Net Assets per Share|Net Assets per Single Share Organovo|Radius Recycling Inc. (RDUS) - Net Assets per Share